Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Jamu
Muhammad Ilham Hamzah
Study Program of Pharmacy, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Makassar, South Sulawesi, 90221
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Cytotoxic Interaction Between Cisplatin and Eclipta alba Extract in HeLa Cervical Cancer Cells Putri Awaliah Aldina; Surawalia Said; Muhammad Ilham Hamzah; Nur Afiq Zaky Ananda; Fityatun Usman; Zulkifli Zulkifli; Widya Hardiyanti; Nurfadilah Nurfadilah; Andi Ulfah Magefirah; Lukman Lukman
Jurnal Jamu Indonesia Vol. 11 No. 3 (2026): Jurnal Jamu Indonesia
Publisher : Tropical Biopharmaca Research Center, IPB University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29244/jji.v11i3.449

Abstract

Cervical cancer remains a major cause of cancer-related mortality among women worldwide. Cisplatin is a first-line chemotherapeutic agent, but its use is limited by resistance and dose-dependent toxicity. This study evaluated the cytotoxic interaction between cisplatin and Eclipta alba extract in HeLa cervical cancer cells. Ethanolic maceration yielded 17.38 g of extract, corresponding to 10.22%. Thin-layer chromatographic screening indicated flavonoids, coumarins, and triterpenoid saponins, while LC–MS/MS tentatively identified eclalbasaponin I, wedelolactone, pinoquercetin, luteolin, and quercitrin. Cytotoxicity was assessed using the MTT assay. The IC₅₀ values were 1.15 ± 0.16 µg/mL for cisplatin and 598.29 ± 42.89 µg/mL for the extract. Under fixed sub-IC₅₀ cisplatin conditions, 0.42 µg/mL, the extract IC₅₀ decreased to 64.97 ± 5.41 µg/mL. Combination index values below 1 suggested synergistic interaction under fixed-dose conditions, indicating a potential dose-sparing strategy requiring further validation.
Co-Authors Andi Ulfah Magefirah Fityatun Usman Lukman Lukman Nur Afiq Zaky Ananda Nurfadilah Nurfadilah Putri Awaliah Aldina Surawalia Said Widya Hardiyanti Zulkifli Zulkifli